Ophthalmic drug-delivery device maker pSivida Corp. posts a $2.7 million net loss in its fiscal third quarter, as revenues shrink following a contract expiration in December.
The expiration of a performance contract with a product-development partner eliminated a big part of the revenue stream at pSivida Corp. (NSDQ:PSDV) during early 2010 and helped send the ophthalmic care company to a $2.7 million net loss during the three months ended March 31.
Revenues fell to $515,000 during the company's fiscal third quarter, down from $3.2 million during the same period last year. The year-ago period included $3 million in payments from Alimera Sciences Inc. (NSDQ:ALIM), which is working with pSivida to develop and market Iluvien, a drug-delivery device to treat diabetic macular edema. That contract expired Dec. 31, 2009, leaving only a similar collaboration pact with drug-maker Pfizer Inc. (NYSE:PFE) as pSivida's lone source of incoming funds.
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
If you read nothing else today, make sure you're still in the know with MassDevice +3.